Optimizing second-line therapy for chronic myeloid leukemia.
Indian J Cancer
;
2012 Jan-Mar; 49(1): 46-56
Article
in English
| IMSEAR
| ID: sea-144551
ABSTRACT
Treatment of chronic myeloid leukemia has evolved from symptom control to long-term disease-free survival with cure potentially round the corner. This required faster, deeper, and longer response. Optimizing treatment decisions therefore requires clear understanding of and strict implementation of guidelines for shift from imatinib. In patients who are resistant to or intolerant of imatinib, second-line TKIs have to be selected carefully. Currently available data show comparable efficacy between nilotinib and dasatinib. With a better safety profile (especially with respect to grade 3 or 4 hematologic toxicity and clinically relevant non-hematologic toxicities), nilotinib becomes the preferred choice in most instances.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Piperazines
/
Pyrimidines
/
Thiazoles
/
Protein-Tyrosine Kinases
/
Humans
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Chromosome Aberrations
/
Fusion Proteins, bcr-abl
/
Treatment Outcome
/
Disease-Free Survival
Type of study:
Practice guideline
/
Prognostic study
Language:
English
Journal:
Indian J Cancer
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS